Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topical aerosol, 10 g a...
FDA Drug Recall #D-0452-2022 — Class II — January 21, 2022
Recall Summary
| Recall Number | D-0452-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 21, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mylan Pharmaceuticals Inc |
| Location | Morgantown, WV |
| Product Type | Drugs |
| Quantity | 233,199/10 g aerosol containers |
Product Description
Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topical aerosol, 10 g aerosol containers, Rx Only, Distributed by Meda Pharmaceuticals Inc, Somerset, New Jersey 08873-1120, NDC 0037-6822-10.
Reason for Recall
cGMP deficiencies
Distribution Pattern
Recalled product was distributed nationwide within the United States.
Lot / Code Information
Lot #: 32925, Exp. date May 2023, 33010, Exp. date June 2023; 33119, 33123, Exp. date August 2023
Other Recalls from Mylan Pharmaceuticals Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0399-2026 | Class II | Isotretinoin Capsules, USP 40 mg, packaged in 3... | Feb 24, 2026 |
| D-0280-2025 | Class II | Prasugrel Tablets, USP, 5 mg, 30-count bottle, ... | Feb 25, 2025 |
| D-1292-2022 | Class I | Insulin Glargine (Insulin glargine-yfgn) Inject... | Jul 5, 2022 |
| D-0845-2022 | Class I | Insulin Glargine (insulin glargine-yfgn) Inject... | Apr 12, 2022 |
| D-0774-2022 | Class II | Rifampin for Injection, USP, 600 mg/vial, One V... | Apr 7, 2022 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.